Expression of B7‐H3 and TIM ‐3 in gastric‐type endocervical adenocarcinoma: prevalence, association with PD‐L1 expression, and prognostic significance
The Journal of Pathology: Clinical Research · 2024
DOI: 10.1002/cjp2.345 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2024. Verfasst von Yao Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Zhejiang University School of Medicine Women's Hospital, Hangzhou, Zhejiang Province, PR China. Hauptthemen laut MEDLINE: Adenocarcinoma, Stomach Neoplasms, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Gastric‐type endocervical adenocarcinoma (GEA) is the second most common subtype of endocervical adenocarcinoma and has a poor prognosis. Anti‐programmed death‐1 and anti‐programmed death‐ligand 1 (PD‐L1) inhibitors have emerged as a major treatment option for GEA; however, data on the expression of other immune checkpoints in GEA are limited. We analyzed the expression of T‐cell immunoglobulin and mucin‐domain containing‐3 (TIM‐3) and B7 homolog 3 protein (B7‐H3) in 58 GEA and investigated their prognostic significance as well as association with PD‐L1 expression and other known prognostic factors. Applying the tumor proportion score (TPS) with a cutoff of 1%, B7‐H3 and TIM‐3 were present in 48.3% and 17.2% of cases, respectively. Applying the combined positive score (CPS) with a cutoff of 1, TIM‐3 expression was present in 70.7% of cases. Moreover, the expression of three checkpoints (B7‐H3, TIM‐3, and PD‐L1) was incompletely overlapping. Patients with B7‐H3 positive tumors (by TPS) or TIM‐3 positive tumors (by TPS) had significantly worse recurrence‐free survival (RFS) and overall survival (OS) (log‐rank). Using CPS, patients with TIM‐3 positive tumors showed significantly worse RFS (log‐rank). Similarly, B7‐H3 positivity (by TPS) and TIM‐3 positivity (by TPS) were associated with worse RFS and OS in univariate analysis. TIM‐3 positivity (by CPS) was associated with worse RFS in univariate analysis and the final Cox multivariate analysis. In conclusion, our results show that (1) B7‐H3 and TIM‐3 are frequently expressed in GEA and their expression overlaps incompletely with PD‐L1; and (2) both B7‐H3 and TIM‐3 are independent negative prognostic markers in GEA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Zhejiang University School of Medicine Women's Hospital, Hangzhou, Zhejiang Province, PR China.
- Department of Pathology, International Peace Maternity and Child Health Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Department of Pathology, Parkland Hospital, Dallas, TX, USA.
- Department of Gynecology, Zhejiang University School of Medicine Women's Hospital, Hangzhou, Zhejiang Province, PR China.
ORCID-Profile: Feng Zhou
Zitieren
APA
Sun, Y., Zhou, X., Lucas, E., Chen, L., Zhang, H., Chen, H., & Zhou, F. (2024). Expression of B7‐H3 and TIM ‐3 in gastric‐type endocervical adenocarcinoma: prevalence, association with PD‐L1 expression, and prognostic significance. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/cjp2.345
Vancouver
Sun Y, Zhou X, Lucas E, Chen L, Zhang H, Chen H, et al. Expression of B7‐H3 and TIM ‐3 in gastric‐type endocervical adenocarcinoma: prevalence, association with PD‐L1 expression, and prognostic significance. The Journal of Pathology: Clinical Research. 2024. doi:10.1002/cjp2.345
BibTeX
@article{Sun2024,
author = {Sun, Yao and Zhou, Xin and Lucas, Elena and Chen, Lili and Zhang, Huijuan and Chen, Hao and Zhou, Feng},
title = {Expression of B7‐H3 and TIM ‐3 in gastric‐type endocervical adenocarcinoma: prevalence, association with PD‐L1 expression, and prognostic significance},
journal = {The Journal of Pathology: Clinical Research},
year = {2024},
doi = {10.1002/cjp2.345}
}
EUVIMED